stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.18
0.82
+4.72%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Return on equity
Dyne Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −81.6%, down 25.9 percentage points from fiscal 2025 (−55.7%). Over the past ten years it has ranged from −137.3% (fiscal 2023) to 162.6% (fiscal 2019); the current reading is higher than 38% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −55.7% | 32.32 |
| FY2024 | −88.0% | 49.28 |
| FY2023 | −137.3% | (83.13) |
| FY2022 | −54.2% | (12.16) |
| FY2021 | −42.0% | (5.89) |
| FY2020 | −36.1% | (198.77) |
| FY2019 | 162.6% | 109.98 |
| FY2018 | 52.7% | — |
Against its own ten years
Low −137.3%
High 162.6%
Ten-year median
−48.1%
Current reading's percentile
38
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| DYN Dyne Therapeutics, Inc. | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)